Evidence map›Paper›PMID 25400988›Full record

ReviewWorld journal of gastrointestinal pathophysiology2014

Biomarkers of Barrett's esophagus.

Yasser Mahrous Fouad, Ibrahim Mostafa, Reem Yehia, Hisham El-Khayat

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastrointestinal pathophysiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Advances in the Diagnosis of Barrett's Esophagus.Diagnostics (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Article
  4. Molecular biomarkers of progression from Barrett's esophagus to esophageal adenocarcinoma.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023
    Article
  5. Molecules involved in the development of Barrett's esophagus phenotype in chronic eosinophilic esophagitis.American journal of physiology. Gastrointestinal and liver physiology · 2022
    Article
  6. Review
  7. Review
  8. Review
  9. Challenges in Endoscopic Therapy of Dysplastic Barrett's Esophagus.Current treatment options in gastroenterology · 2019
    Review
  10. Barrett's oesophagus: Current controversies.World journal of gastroenterology · 2017
    Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yasser Mahrous FouadYasser Mahrous Fouad, Reem Yehia, Gastroenterology and Hepatology Unit, Tropical Medicine Department, Minia University, Minia 11432, Egypt.
Ibrahim MostafaYasser Mahrous Fouad, Reem Yehia, Gastroenterology and Hepatology Unit, Tropical Medicine Department, Minia University, Minia 11432, Egypt.
Reem YehiaYasser Mahrous Fouad, Reem Yehia, Gastroenterology and Hepatology Unit, Tropical Medicine Department, Minia University, Minia 11432, Egypt.
Hisham El-KhayatYasser Mahrous Fouad, Reem Yehia, Gastroenterology and Hepatology Unit, Tropical Medicine Department, Minia University, Minia 11432, Egypt.
Minia University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Barrett's esophagus is the strongest risk for esophageal adenocarcinoma (EAC). Metaplasia in patients with BE may progress to dysplasia and then invasive carcinoma. Well-defined diagnostic, progressive, predictive, and prognostic biomarkers are needed to identify the presence of the disease, estimate the risk of malignant transformation, and predict the therapeutic outcome and survival of EAC patients. There are many predictive and prognostic markers that lack substantial validation, and do not allow stratification of patients with gastroesophageal reflux disease in clinical practice for outcome and effectiveness of therapy. In this short review we summarize the current knowledge regarding possible biomarkers, focusing on the pathophysiologic mechanisms to improve prognostic and therapeutic approaches.

Indexed as

Barrett’s esophagusBiomarkersEsophageal adenocarcinoma

Identifiers

PMID25400988
PMCPMC4231509
OpenAlexW2090671976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.